6078-07-5Relevant academic research and scientific papers
Nitric oxide donor β2-agonists: Furoxan derivatives containing the fenoterol moiety and related furazans
Federica Buonsanti,Bertinaria, Massimo,Di Stilo, Antonella,Cena, Clara,Fruttero, Roberta,Gasco, Alberto
, p. 5003 - 5011 (2008/03/12)
The structure of fenoterol, a β2-adrenoceptor agonist used in therapy, has been joined with furoxan NO-donor moieties to give new NO-donor β2-agonists. The furazan analogues, devoid of the property to release NO, were also synthesized for comparison. All the compounds retained β2-agonistic activity at micromolar or submicromolar concentration when tested on guinea pig tracheal rings precontracted with carbachol. Among the furoxan derivatives, the NO contribution to trachea relaxation was evident with product 15b at micromolar concentrations. All the new NO-donor hybrids were able to dilate rat aortic strips precontracted with phenylephrine. Both furoxan and furazan derivatives displayed antioxidant activity greater than that of fenoterol.
Carbazolyl-substituted ethanolamines as selective beta -3 agonists
-
, (2008/06/13)
PCT No. PCT/US97/15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98/09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
